Home Page

Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2016

(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers )

Charenton-le-Pont, France (May 4, 2016 - 6.00 p.m.) - As of April 30, 2016, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

(*) Shares held by the Company.

About Essilor
The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux ^® , Crizal ^® , Transitions ^® , Eyezen ^TM , Xperio ^® , Foster Grant ^® , Bolon ^TM and Costa ^® . It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €6.7 billion in 2015 and employs 61,000 people worldwide. It markets its products in more than 100 countries and has 32 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world. For more information, please visit www.essilor.com .
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

------------------------

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16